Shares of Replimune Group REPL have surged 131.1% over the past three months, fueled by positive regulatory updates. In ...

No matter whether you are a seasoned programmer or you simply want to take your first steps in writing code, Repl.it wants to help you get from idea to result as fast as possible — without complicated ...

You're currently following this author! Want to unfollow? Unsubscribe via the link in your email. Follow Rosalie Chan Every time Rosalie publishes a story, you’ll get an alert straight to your inbox!

Among the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in The Trade Desk Inc (Symbol: TTD), where a total of 69,953 contracts have traded so far, ...

) has been revised to $10.84 / share. This is an increase of 48.75% from the prior estimate of $7.29 dated September 27, 2025. The price target is an average of many targets provided by analysts. The ...

Replimune Group, Inc., a clinical-stage biotechnology company, focuses on the development and commercialization of oncolytic immunotherapies to treat cancer. The company’s proprietary oncolytic ...

Shares of Replimune Group, Inc. (NASDAQ:REPL) are rising Monday after the clinical stage biotechnology company shared an important regulatory update. What To Know: Replimune said the U.S. Food and ...

If you are following Replimune Group (REPL) right now, you’re not alone. The company’s recent announcement about completing a Type A meeting with the FDA on its lead drug candidate, RP1, has put it ...

We recently published 10 Stocks Losing Big Amid Market Boom. Replimune Group, Inc. (NASDAQ:REPL) is one of the worst performers on Thursday. Replimune extended losses to a second consecutive day on ...